Clinical Trial

Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis

Study acronym: RegenOSF
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 11, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Oral Submucous Fibrosis (OSF) is a chronic, progressive, potentially malignant disorder characterized by mucosal stiffness, trismus, and burning sensation. This interventional clinical trial evaluates the therapeutic effectiveness of alternating weekly intralesional Triamcinolone Acetonide (TA) and Platelet-Rich Plasma (PRP) injections compared to standard Triamcinolone therapy alone. The purpose is to determine whether sequential anti-inflammatory (TA) and regenerative (PRP) stimulation can produce superior clinical improvement in mouth opening, burning sensation, and mucosal flexibility compared to corticosteroid therapy alone.
Trial Details
NCT Number NCT07277998
Lead Sponsor Karachi Medical and Dental College
Conditions Oral Submucous Fibrosis
Enrollment 40 participants
Start Date 2026-03
Primary Completion 2026-07 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-12-11